Get the CTMX Research Report and
Also Receive Our Top Trades for 2017!

CytomX Therapeutics, Inc.

Bristol-Myers Squibb Company and CytomX Therapeutics, Inc., a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today announced an expansion of their 2014 strategic collaboration to discover novel therapies that will include up to eight additional targets using CytomX’s proprietary Probody platform. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of … (See Research Report)
Download Research Report
on CTMX Now